CLRB · Nasdaq
It filed on time and stood behind its numbers. Of companies scoring zero, 4.0% were delisted, went bankrupt, restated or stopped filing within the following year.
Hover or tap a dot to see the filings behind that score.
Cellectar Biosciences, Inc. (the “Company”) has determined that it is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q”) by November 14, 2024, the original due date for such filing, without unreasonable effort or expense due to the circumstances described below. The Company recently identified that certain warrants and preferred stock issued prior to 2023 had not been accounted for properly. In response, the Company had new audits performed of fiscal years 2023 and 2022. Those restated financial statements, the related quarterly financial statements for those fiscal years, and restated financial statements for the quarter ended March 31, 2024, were filed on October 29, 2024. Additionally, the Company’s 10-Q for the quarter and six months ended June 30, 2024, was also filed on October 29, 2024. As a result of the timing of the filings listed above, the Company has been unable to complete the preparation and review of the Form 10-Q for the quarter ended September 30, 2024, in time to file within the prescribed time period without unreasonable effort or expense. The Company anticipates filing the Form 10-Q within the five-day extension provided by Rule 12b-25(b). The Company will continue to devote the resources necessary to file its Form 10-Q for the quarter ended September 30, 2024, within that time
NT 10-Q, filed 2024-11-13 · restatement
Cellectar Biosciences, Inc. (the “Company”) has determined that it is unable to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 (the “Form 10-Q”) by November 14, 2024, the original due date for such filing, without unreasonable effort or expense due to the circumstances described below. The Company recently identified that certain warrants and preferred stock issued prior to 2023 had not been accounted for properly. In response, the Company had new audits performed of fiscal years 2023 and 2022. Those restated financial statements, the related quarterly financial statements for those fiscal years, and restated financial statements for the quarter ended March 31, 2024, were filed on October 29, 2024. Additionally, the Company’s 10-Q for the quarter and six months ended June 30, 2024, was also filed on October 29, 2024. As a result of the timing of the filings listed above, the Company has been unable to complete the preparation and review of the Form 10-Q for the quarter ended September 30, 2024, in time to file within the prescribed time period without unreasonable effort or expense. The Company anticipates filing the Form 10-Q within the five-day extension provided by Rule 12b-25(b). The Company will continue to devote the resources necessary to file its Form 10-Q for the quarter ended September 30, 2024, within that time
Cellectar Biosciences, Inc. (the “Company”) has determined that it is unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2024 (the “Form 10-Q”) by August 14, 2024, the original due date for such filing, without unreasonable effort or expense due to the circumstances described below. As disclosed in its Current Report on Form 8-K dated August 9, 2024, the Company determined that it is necessary to re-evaluate the Company’s accounting treatment for the warrants that it issued as part of a financing it completed in October 2022 and concluded that its previously issued (i) audited consolidated financial statements for the fiscal years ended December 31, 2023 and December 31, 2022, contained in its Annual Reports on Form 10-K and (ii) unaudited interim condensed consolidated financial statements for the periods ending March 31, 2023, June 30, 2023, September 30, 2023, and March 31, 2024, contained in its Quarterly Reports on Form 10-Q should no longer be relied upon due to errors in such financial statements, and therefore a restatement of these prior financial statements is required. As a result, the Company is in the process of re-evaluating the accounting treatment of the aforementioned warrants and preparing the related restatements and has been unable to complete the preparation and review of the Form 10-Q for the quarter ended June 30, 2024, in time to file within the prescribed time period without unreasonable effort or expense. While the Company continues to work expeditiously to conclude the re-evaluation of the accounting treatment, the restatements and the preparation and review of the Form 10-Q for the quarter ended June 30, 2024, as soon as practicable, the Company does not anticipate filing the Form 10-Q within the five-day extension provided by Rule 12b-25(b). The Company will continue to devote the resources necessary to file its Form 10-Q for the quarter ended June 30, 2024, as soon as practicable
2024-08-09accounts declared unreliable SEC →
2024-07-11auditor changed or resigned SEC →
reportingrisk.com scores every active US filer on three things a company tells the SEC about itself: late-filing notices on Form NT, 8-K item 4.02 (past accounts declared unreliable) and 4.01 (auditor changes). 1,012 are flagged today.
Every score is frozen and checked twelve months later. Across 91,452 of them, a company scoring 4 or more ended that year delisted, bankrupt, restated or silent 17.2% of the time, against 4.0% for a clean record. Scores before 2026-09-27 were reconstructed from the filing history as it stood at each date, so the record is a backtest rather than years of live calls.
See the ledger → Every company the score flagged that later failed, what it told the SEC on the way down, and the ones it missed.Every item above is a filing this company
made with the SEC.
Snapshot 2026-11-04 · data from SEC EDGAR (public domain) · not
investment advice